Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Change in Acquisitions & Divestments (2016 - 2025)

Historic Change in Acquisitions & Divestments for Fate Therapeutics (FATE) over the last 10 years, with Q3 2025 value amounting to $81.4 million.

  • Fate Therapeutics' Change in Acquisitions & Divestments fell 1020.18% to $81.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $306.5 million, marking a year-over-year decrease of 1609.07%. This contributed to the annual value of $330.7 million for FY2024, which is 3076.24% down from last year.
  • Fate Therapeutics' Change in Acquisitions & Divestments amounted to $81.4 million in Q3 2025, which was down 1020.18% from $71.6 million recorded in Q2 2025.
  • Fate Therapeutics' 5-year Change in Acquisitions & Divestments high stood at $263.1 million for Q4 2021, and its period low was $60.9 million during Q4 2024.
  • Over the past 5 years, Fate Therapeutics' median Change in Acquisitions & Divestments value was $111.6 million (recorded in 2021), while the average stood at $124.0 million.
  • In the last 5 years, Fate Therapeutics' Change in Acquisitions & Divestments skyrocketed by 113808.94% in 2021 and then crashed by 4277.7% in 2023.
  • Fate Therapeutics' Change in Acquisitions & Divestments (Quarter) stood at $263.1 million in 2021, then plummeted by 36.57% to $166.9 million in 2022, then plummeted by 42.78% to $95.5 million in 2023, then crashed by 36.21% to $60.9 million in 2024, then soared by 33.7% to $81.4 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $81.4 million for Q3 2025, versus $71.6 million for Q2 2025 and $92.5 million for Q1 2025.